文献速递骨质疏松与钙磷/甲状旁腺

特立帕肽后使用地舒单抗治疗绝经前特发性骨质疏松症女性

Denosumab After Teriparatide in Premenopausal Women With Idiopathic Osteoporosis.
PubMed 文献 · J Clin Endocrinol Metab · 2022-01-01

这项2B期扩展研究纳入完成24个月特立帕肽治疗的绝经前特发性骨质疏松症女性,予地舒单抗60 mg每6个月一次共24个月。32例完成12个月、29例完成24个月,腰椎骨密度分别增加5.2±2.6%和6.9±2.6%,总髋分别增加2.9±2.4%和4.6±2.8%,股骨颈分别增加3.0±3.8%和4.7±4.9%。结论支持序贯使用特立帕肽和地舒单抗以增加骨密度。

要点

  • 完成特立帕肽治疗的绝经前特发性骨质疏松症女性,序贯地舒单抗60 mg每6个月一次共24个月。
  • 地舒单抗12个月时腰椎骨密度增加5.2±2.6%,24个月时增加6.9±2.6%。
  • 整个24个月特立帕肽加24个月地舒单抗期间,腰椎骨密度增加21.9±7.8%(P < .0001)。

核心结论

  • 这些数据支持在患有严重骨质疏松症的绝经前女性中使用序贯特立帕肽和地舒单抗以增加骨密度。

研究设计与样本

  • 这是一项预先计划的2B期扩展研究。
  • 研究纳入完成24个月特立帕肽治疗的绝经前特发性骨质疏松症女性,予地舒单抗60 mg每6个月一次,共24个月。
  • 主要结局指标为12个月时腰椎骨密度的组内变化。

主要发现

  • 完成特立帕肽后,32例参与者接受地舒单抗治疗12个月,29例接受24个月。
  • 12个月和24个月时,腰椎骨密度分别增加5.2±2.6%和6.9±2.6%。
  • 12个月和24个月时,总髋骨密度分别增加2.9±2.4%和4.6±2.8%。
  • 12个月和24个月时,股骨颈骨密度分别增加3.0±3.8%和4.7±4.9%。
  • 整个24个月特立帕肽加24个月地舒单抗治疗期间,腰椎骨密度增加21.9±7.8%,总髋增加9.8±4.6%,股骨颈增加9.5±4.7%(均P < .0001)。

关键数值与推荐

  • 小梁骨评分增加5.8±5.6%(P < .001)。
  • 血清骨转换标志物在地舒单抗治疗3个月时下降75%至85%,并在12个月内保持抑制。
  • 地舒单抗总体耐受良好。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: We have previously reported that teriparatide is associated with substantial increases in bone mineral density (BMD) at the lumbar spine (LS), total hip (TH), and femoral neck (FN) and small declines at the distal radius in 41 premenopausal women with idiopathic osteoporosis (IOP), all severely affected with low trauma fractures and/or very low BMD. Effects of teriparatide dissipate if not followed by antiresorptives. OBJECTIVE: To assess the effects of 12 and 24 months of denosumab in premenopausal women with IOP completing 24 months of teriparatide. METHODS: This was a preplanned phase 2B extension study. Premenopausal women with IOP who had completed a course of teriparatide received denosumab 60 mg every 6 months over 24 months. The main outcome measure was within-group change in BMD at the LS at 12 months. Secondary outcomes include change in 12-month BMD at other sites, 24-month BMD at all sites, trabecular bone score (TBS), and bone turnover markers (BTMs). RESULTS: After completing teriparatide, 32 participants took denosumab for 12 months and 29 for 24 months, with statistically significant increases in BMD at the LS (5.2 ± 2.6% and 6.9 ± 2.6%), TH (2.9 ± 2.4% and 4.6 ± 2.8%), and FN (3.0 ± 3.8% and 4.7 ± 4.9%). Over the entire 24-month teriparatide and 24-month denosumab treatment period, BMD increased by 21.9 ± 7.8% at the LS, 9.8 ± 4.6% at the TH, and 9.5 ± 4.7% at the FN (all P < .0001). TBS increased by 5.8 ± 5.6% (P < .001). Serum BTM decreased by 75% to 85% by 3 months and remained suppressed through 12 months of denosumab. Denosumab was generally well tolerated. CONCLUSION: These data support the use of sequential teriparatide and denosumab to increase BMD in premenopausal women with severe osteoporosis.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Shane E, Shiau S, Recker RR, et al. Denosumab After Teriparatide in Premenopausal Women With Idiopathic Osteoporosis. J Clin Endocrinol Metab. 2022. PMID: 34849989. doi:10.1210/clinem/dgab850

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。